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GLYCOSYLATE DERIVATIVES OF 
MITHRAMYCIN, METHOD OF 
PREPARATION AND USES THEREOF 
CROSS-REFERENCE TO RELATED 
APPLICATIONS 
This application is ?led under the provisions of 35 U.S.C. 
§371 and claims the priority of International Patent Applica 
tion No. PCT/ES2008/070015 ?led on 4 Feb. 2008 entitled 
“Glycosylate Derivatives of Mithramycin, Method of Prepa 
ration and Uses Thereof” in the name of Jurgen Rohr, et al., 
which claims priority of Spanish Patent Application No. 
P200700378 ?led on 6 Feb. 2007, both of which are hereby 
incorporated by reference herein in their entirety. 
The invention belongs to the pharmaceutical ?eld and spe 
ci?cally relates to compounds with application in oncology, 
with a chemical structure derived from mithramycin and 
which are obtained by microorganism fermentation. 
STATE OF THE ART 
Mithramycin (MTM) is an antitumor drug produced by 
microorganisms of the Streptomyces genus, including Strep 
tomyces argillaceus ATCC 12956. This drug is the most 
important representative of the group of aureolic acid, and it 
is used for the treatment of testicular carcinoma, Paget’s 
disease and hypercalcaemia caused by bone lesions associ 
ated to cancer (Oncology 1973, 28,147-163; Biochem. Bio 
phys. Res. Commun. 1993, 195, 1245-1253; Treat. Endo 
crinol. 2002, 1, 241-257; Treat. Endocrinol. 2003, 2, 273 
292). MTM is furthermore a neuroprotective agent which 
could be useful for the treatment of neurological diseases 
such as stroke, amyotrophic lateral sclerosis, Parkinson’s dis 
ease, Huntington’s disease, multiple sclerosis and viral 
encephalitis (J. Neurosci. 2004, 24, 10335-10342; J. Biol. 
Chem. 2006, 281, 16672-16680). Furthermore, MTM has 
antibiotic activity (Antibiot. Chemother. 1962, 12, 182-186). 
The chemical structure of MTM is shown in FIG. 1. The 
group of aureolic acid compounds includes MTM, chromo 
mycinA3, olivomycinA, UCH9 and duramycin (Appl. Micro 
biol. Biotechnol. 2006, 73, 1-14). All ofthem contain a tricy 
clic core with a polyketide origin, with a highly 
functionalized side chain at carbon 3. The residue at carbon 7 
can be a hydrogen atom or a short-chain alkyl. Likewise, these 
compounds have 4-6 deoxysugars linked in the form of trisac 
charide or tetrasaccharide (at carbon 2) and monosaccharide 
or disaccharide (at carbon 6). Aureolic acid compounds differ 
in the nature and linking of their saccharide chains, contain 
ing different 2,6-dideoxysugars. These structural variations 
are responsible for the subtle differences existing among the 
members of the group as regards their DNA binding and their 
biological activity pro?le. It is well known that the glycosy 
lation pattern of antitumor drugs which act by binding to 
DNA, as is the case of MTM, is very important in their 
biological activity (Biopolymers 2000, 54, 104-114). There 
fore, obtaining novel derivatives of MTM with altered glyco 
sidic patterns can generate drugs with improved activity. 
The cluster of genes responsible for MTM biosynthesis has 
been widely studied (Appl. Microbiol. Biotechnol. 2006, 73, 
1-14). MTM biosynthesis in Streptomyces argillaceus 
includes the condensation of 10 units of acyl-coenzyme A to 
generate a tetracyclic intermediate, called premithramyci 
none (FIG. 2). Then, 5 units of deoxysugars are successively 
added, tetracyclic intermediates with 3 sugars and with 5 
sugars being generated. The glycosyltransferases thGIII 
and thGIV are responsible for the formation of the trisac 
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2 
charide, whereas glycosyltransferases thGI and thGII 
catalyze the formation of the disaccharide. Finally, the cleav 
age of one of the rings, followed by the reduction of a keto 
group in the side chain, generates MTM. 
There is currently a great need for novel antitumor agents, 
with improved activity, with fewer undesirable side effects 
and with higher selectivity, compared to currently used drugs. 
Traditionally, the pharmaceutical industry has developed 
novel drugs by means of two main routes: (1) search for novel 
natural products, and (2) chemical modi?cation and/or syn 
thesis of certain compounds. These methods are still useful, 
but usually require very important investments of resources 
(time, money, energy), since it is normally necessary to ana 
lyze thousands of products in order to ?nd a novel promising 
compound. The development of recombinant DNA technol 
ogy has opened up an interesting ?eld of research for the 
generation of novel bioactive compounds by means of the 
manipulation of genes involved in the biosynthesis of antitu 
mor agents, mainly of bacteria of the actinomycete group 
(Trends Biotechnol. 2001, 19, 449-456; J. Mol. Microbiol. 
Biotechnol. 2005, 9, 77-85; Curr. Opin. Drug Discov. Devel. 
2005, 8, 748-756; J. Ind. Microbiol. Biotechnol. 2006, 33, 
560-568; Curr. Opin. Microbiol. 2006, 9, 252-260). These 
techniques can also be used to improve the production of 
already known natural compounds, since natural strains usu 
ally produce low concentrations of the metabolite of interest. 
DESCRIPTION OF THE INVENTION 
The present invention provides novel bacterial strains 
derived from Streptomyces argillaceus. These strains are 
obtained by means of introducing certain additional nucleic 
acids in existing bacterial strains, which can be: (a) Strepto 
myces argillaceus, or (b) strains derived from Streptomyces 
argillaceus. The strains of section (b) can be obtained (among 
other methods) by means of the inactivation of one (or sev 
eral) of the genes responsible for mithramycin biosynthesis, 
and are useful for obtaining derivatives of MTM (US 2005/ 
0192432 A1 ; J. Am. Chem. Soc. 2003, 125, 5745-5753; J. Am. 
Chem. Soc. 2002, 124, 1606-1614; Mol. Gene. Genet. 2001, 
264, 827-835; FEMSMicrobiol. Lett. 2000, 186, 61-65; Mol. 
Gene. Genet. 2000, 262, 991-1000;J. Biol. Chem. 2000, 275, 
3065-3074; Mol. Gene. Genet. 1999, 261, 216-225; Chem. 
Biol. 1999, 6, 19-30; J. Bacteriol. 1999, 181, 642-647; J. 
Bacteriol. 1998, 180, 4929-4937; J. Bacteriol. 1997, 179, 
3354-3357; Mol. Gene. Genet. 1996, 251, 692-698; Gene 
1996, 172, 87-91). An example of strain of section (b), which 
can be used in the present invention, is Streptomyces argilla 
ceus M7U1, which was obtained from Streptomyces argilla 
ceus by means of the inactivation of the mth gene (Mol. 
Gene. Genet. 2001, 264, 827-835). The mth gene encodes 
a 4-ketoreductase involved in D-oliose biosynthesis, and its 
inactivation results in the accumulation of premithramyci 
none and premithramycin A. Another example of strain of 
section (b) is Streptomyces argillaceus M7W1, which was 
obtained from Streptomyces argillaceus by means of the inac 
tivation of the mth gene (US 2005/0192432 A1; J. Am. 
Chem. Soc. 2003, 125, 5745-5753). The mth gene encodes 
a ketoreductase, and its inactivation results in the accumula 
tion of demycarosyl-MTM-SK, MTM-SA, MTM-SDK, and 
MTM-SK. 
The introduction of nucleic acids in Streptomyces argilla 
ceus (or in derivative strains) can be carried out by means of 
protoplast transformation, conjugation, or other known meth 
ods (such as those described in Practical Streptomyces genet 
ics, The John Innes Foundation, Norwich, Great Britain, 
2000), such that the nucleic acids are replicable in the organ 
US 8,426,169 B2 
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ism, either in the form of an extrachromosomal element or 
integrated in the chromosome of the organism. Said nucleic 
acids encode enzymes for the biosynthesis of different sugars; 
said sugars are not normally produced by Slreplomyces 
argillaceus. Examples of nucleic acids useful for the present 
invention are those contained in the following plasmids 
(which are mentioned by way of example): pLNBlV (Chem. 
Biol. 2002, 9, 721-729; J Nat. Prod. 2002, 65, 1685-1689), 
pRHAM (J. Mol. Microbiol. Biotechnol. 2000, 2, 271-276), 
pLN2 (Chem. Biol. 2002, 9, 721-729), pLNR (Chem. Biol. 
2002, 9, 721-729), and pFL845 (Chem. Commun. (Camb). 
2005 Mar. 28; (12): 1 604-6). The mentioned plasmids contain 
nucleic acids encoding enzymes for the biosynthesis of the 
following sugars (in the form of NDP derivatives), respec 
tively: L-digitoxose, L-rhamnose, L-olivose, D-olivose, and 
D-amicetose. However, other nucleic acids which encode 
enzymes for the biosynthesis of other unmentioned sugars 
can be used in the present invention. 
The bacterial strains of this invention can be cultured in any 
suitable medium, in conditions allowing their growth, as is 
described in Gene 1996, 172, 87-91; J. Bacteriol. 1998, 180, 
4929-4937; J. Am. Chem. Soc. 2003, 125, 5745-5753. After 
several days of incubation, these cultures contain a high 
amount of cells (mycelium), together with a mixture of com 
pounds, including derivatives of MTM. The cultures are then 
subjected to processes for the separation of a liquid phase 
(supernatant) and a solid phase (mycelium). The two phases 
are then subjected, separately, to several processes which can 
include extraction with several organic solvents, and several 
types of chromatography (such as HPLC, high performance 
liquid chromatography), for the purpose of obtaining the 
derivatives of MTM in the form of pure compounds. The 
derivatives of MTM are antitumor agents and also act as 
neuroprotective agents. 
Likewise, the present invention provides compounds char 
acterized by the following formula (I): 
wherein 
R1 is hydrogen, hydroxyl (OH), a hydroxyl group protected 
with a protecting group, a monosaccharide of formula (ll) 
(11) 
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4 
R2 is hydrogen, a protecting group, a monosaccharide of 
formula (III), 
(111) 
Me 
(1V) 
(V) 
R180 
Me Me 
O O 
R O 16 0% 
a disaccharide of formula (V 1), 
(V1) 
Me 
Me 
R O 
20 Me ‘0 
or a disaccharide of formula (V11). 
(V11) 
R240 
Me Me 
R220 O 0% Me 
OR23 
a monosaccharide of formula QilV), 
(XIV) 
R O 
24 M6 
0 
R250 
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a disaccharide of formula C(V), 
(XV) 
Me Me 
OR27 
or a disaccharide of formula (XVI) 
(XVI) 
Me Me 
Me 
OR30 
R3: R4: R5: R6: R7 and R8: R10: R11: R12: R13: R14: R15: R16: 
R17, R18: R19, R20, R21, R22, R23 and R24, R25, R26: R27, 28, 
R29, R30, R31 are each and independently hydrogen or a pro 
tecting group; 
20 
6 
R9 is hydrogen, a methyl group, or an alkyl group; and 
the stereochemistry of carbons a, b, c, d and e is R, S or a 
mixture of both. 
The protecting group can consist of an alkyl group, a 
cycloalkyl group, a heterocyclic cycloalkyl group, a hydroxy 
alkyl group, a halogenated alkyl group, an alkoxyalkyl group, 
an alkenyl group, an alkynyl group, an aryl group, a hetero 
cyclic aryl group, an alkylaryl group, an ester group, a car 
bonate group, a carboxylic acid group, an aldehyde group, a 
ketone group, a urethane group, a silyl group, a sulfoxo group 
or a combination thereof. 
The compounds of formula (I) include those Wherein: 
R3, R4, R5 and R6 are hydrogen; or 
R3, R4, R5, R6, R7 and R8 are hydrogen; or 
R9 is methyl; or 
the stereochemistry at carbons a, b, c and d is S, and the 
stereochemistry at carbon e is R; or 
R3: R4, R5, R6, R7, R8: R10, R11, R12, R13, R14, R15, R16, 
R17: R18: and R19: R20: R21: R22: R23: R24: R25: R26: R27: R 28: 
R29, R30, R3 1 are hydrogen, R9 is methyl, the stereochemistry 
at carbons a, b, c and d is S, and the stereochemistry at carbon 
e is R. 
In particular, the present invention provides, among others, 
the compounds With the following formulas (VIII, IX, X, XI, 
XII, XIII): 
(VIII) 
(1X) 
HO 
Me 
OH 
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-continued 
(X) 
Me 
HO 
Me 
M 
6 O HO O 
HO 0 
Me 
OH 
(X1) 
Me 
How/0 HO 
Me 
Me HO Me HO O 
HO O O O 0 
Me 
OH 
(X11) 
Me 
PIG/Ev HO 
Me 
HOMe O 
HO 
O 0 
HO 
(XIII) 
HO 
HO O O 0 
Me O 
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-continued 
(XVII) 
(XVIII) 
Me 
HO M6 0 
HO 
O 0 
OH 
(XIX) 
Me 
How HO 
(U) 
HO 
HO O HO O O 
O 
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-continued 
12 
09(1) 
HO 
OH 
The compounds of the invention are tumor growth inhibi 
tors and are therefore useful in the treatment of cancer. 
Thus, the pharmaceutical compositions comprising an 
effective amount of a compound of formula I or a pharma 
ceutically acceptable salt or solvate thereof together with a 
pharmaceutically acceptable excipient are object of the 
present invention. 
The use of a compound of formula I or a pharmaceutically 
acceptable salt or solvate thereof in the manufacture of a 
medicinal product is also object of the present invention. 
The use of a compound of formula I or a pharmaceutically 
acceptable salt or solvate thereof for inhibiting the growth of 
a tumor is also object of the present invention. 
As used herein, “inhibiting” means decreasing, slowing 
down or stopping. Therefore, a compound of this invention 
can decrease, slow down or stop the growth of a tumor cell. As 
used herein, “growth” means increase in size or proliferation 
or both. Therefore, a compound of this invention can inhibit 
the size increase of a tumor cell and/ or can prevent the tumor 
cell from dividing and the number of tumor cells from 
increasing. A “tumor cell” is a cell forming a neoplasm (new 
growth), which can be cancerous (malignant) or non-cancer 
ous (benign). A cancerous tumor cell can invade the normal 
tissues around it and blood/lymph vessels and form 
metastases in tissues far from the original tumor. In contrast, 
a non-cancerous tumor cell can grow and compress adjacent 
normal tissues but cannot invade normal tissues and blood/ 
lymph vessels and cannot form metastases in tissues far from 
the original tumor. 
The use of a compound of formula I or a pharmaceutically 
acceptable salt or solvate thereof for treating cancer is also 
object of the present invention. 
The use of a compound of formula I or a pharmaceutically 
acceptable salt or solvate thereof in the manufacture of a 
medicinal product with antitumor activity is also object of the 
present invention. 
The use of a compound of formula I or a pharmaceutically 
acceptable salt or solvate thereof in the manufacture of a 
medicinal product for the treatment of cancer is also object of 
the present invention. 
A method for treating a subject, including a human being, 
diagnosed with cancer, consisting of treating said subject 
with a therapeutically effective amount of a compound of 
formula I or a pharmaceutically acceptable salt or solvate is 
also object of the present invention. 
As used herein, a “subject” can include domesticated ani 
mals (for example, cats, dogs, etc.), livestock (for example, 
cows, horses, pigs, sheep, goats, etc.), laboratory animals (for 
20 
25 
35 
40 
45 
50 
55 
60 
65 
example, mice, rabbits, guinea pigs, etc.) and birds. The sub 
ject is preferably a mammal such as a primate, and, more 
preferably, a human being. 
In general, an “effective amount” of a compound is that 
amount necessary to achieve the desired result. For example, 
the effective amount of a compound of the present invention 
treats the cancer by inhibiting the growth of the cells forming 
the tumor, thereby preventing invasion of normal tissues and 
blood/lymph vessels by the tumor cells and, therefore pre 
venting metastasis. Examples of cancers that can be treated 
include, but are not limited to, lung, colon, ovarian, prostate, 
testicular, melanoma, kidney, breast, central nervous system 
and leukemia. The expression “acceptable pharmaceutical 
composition” consists of a biologically suitable material, i.e., 
the material may be administered to the subject without caus 
ing substantially deleterious biological effects. 
The doses or amounts of the compounds of the invention 
must be suf?ciently large to cause the desired effect. How 
ever, the dose must not be so large that it causes adverse side 
effects, for example unwanted cross-reactions, anaphylactic 
reactions, and the like. Generally, the dose will vary with age, 
condition, sex and the degree of disease of the subject, and can 
be determined by any person skilled in the art. The dose can 
be adjusted by each physician, based on the clinical condition 
of the subject involved. The dose, dosing regimen and route of 
administration can be varied. The doses and the dosing regi 
men currently used for MTM provide a guideline for the 
doses and dosing regimen that can be used for the novel 
derivatives of MTM (see for example Cancer T real. Rep. 
1979, 63, 1835-1838; Ann. Intern. Med. 1975, 83, 659-660). 
The use of a compound of formula I or a pharmaceutically 
acceptable salt or solvate thereof in the manufacture of a 
medicinal product for the treatment of Paget’s disease is also 
object of the present invention. 
A method for treating a subject, including a human being, 
diagnosed with Paget’s disease, consisting of treating said 
subject with a therapeutically effective amount of a com 
pound of formula I or a pharmaceutically acceptable salt or 
solvate is also object of the present invention. The subject can 
be a mammal, preferably a human being, and the compound 
can be, among other routes, parenterally administered. 
The use of a compound of formula I or a pharmaceutically 
acceptable salt or solvate thereof in the manufacture of a 
medicinal product for the treatment of hypercalcaemia is also 
object of the present invention. 
A method for treating a subject, including a human being, 
diagnosed with hypercalcaemia, consisting of treating said 
subject with a therapeutically effective amount of a com 
pound of formula I or a pharmaceutically acceptable salt or 
US 8,426,169 B2 
13 
solvate is also object of the present invention. The subject can 
be a mammal, preferably a human being, and the compound 
can be, among other routes, parenterally administered. 
The use of a compound of formula I or a pharmaceutically 
acceptable salt or solvate thereof in the manufacture of a 
medicinal product for the treatment of hypercalciuria is also 
object of the present invention. 
A method for treating a subject, including a human being, 
diagnosed with hypercalciuria, consisting of treating said 
subject with a therapeutically effective amount of a com 
pound of formula I or a pharmaceutically acceptable salt or 
solvate is also object of the present invention. The subject can 
be a mammal, preferably a human being, and the compound 
can be, among other routes, parenterally administered. 
The use of a compound of formula I or a pharmaceutically 
acceptable salt or solvate thereof in the manufacture of a 
medicinal product for the treatment of neurological diseases 
is also object of the present invention. 
A method for treating a subject, including a human being, 
diagnosed with a neurological disease, consisting of treating 
said subject with a therapeutically effective amount of a com 
pound of formula I or a pharmaceutically acceptable salt or 
solvate is also object of the present invention. The subject can 
be a mammal, preferably a human being, and the compound 
can be, among other routes, parenterally administered. 
Examples of neurological diseases that can be treated 
include, but are not limited to, neurodegenerative diseases 
such as Parkinson’ s, Alzheimer’s, and Huntington’ s diseases. 
The compounds of the invention can be useful for the 
research in biochemistry or cell biology. For example, the 
compounds can be useful for blocking the expression of c-Src 
(and other Spl-dependent enzymes) in osteoclasts or other 
cell types. 
Any of the compounds of the invention can be therapeuti 
cally used forming part of an acceptable pharmaceutical com 
position. Any person skilled in the art can create acceptable 
pharmaceutical compositions, which may consist of sterile 
water solutions, saline solutions, or buffered solutions at 
physiological pH. Any of the compounds of the invention can 
be prepared in the form of pharmaceutical composition. The 
pharmaceutical compositions may include several carrier 
agents, thickeners, diluents, buffers, preservatives, surfac 
tants, and others, in addition to the compound of the inven 
tion. The pharmaceutical compositions may also include 
active ingredients such as antimicrobial agents, anti-in?am 
matory agents, anesthetic agents, etc. 
The compounds of the invention can be administered to the 
subject in several different ways depending on whether the 
treatment is to be local or systemic, and depending on the area 
to be treated. Thus, for example, a compound of the present 
invention can be administered in the form of ophthalmic 
solution, for application in the surface of the eye. Further 
more, a compound can be administered to a subject vaginally, 
rectally, intranasally, orally, by inhalation, or parenterally, by 
intradermal, subcutaneous, intramuscular, intraperitoneal, 
intrarectal, intra-arterial, intralymphatic, intravenous, 
intrathecal and intratracheal routes. Parental administration, 
if used, is generally carried out by means of injection. 
Inj ectables can be prepared in different forms, such as liquid 
solutions or suspensions, solid forms suitable for being dis 
solved or suspended prior to injection, or as emulsions. Other 
forms of parenteral administration use slow or sustained 
release systems, such that a constant dose is maintained (see, 
for example, U.S. Pat. No. 3,710,795). Preparations for 
parenteral administration include sterile aqueous or non 
aqueous solutions, suspensions, and emulsions which may 
further contain buffers and diluent additives and others. 
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Examples of non-aqueous solvents are: propylene glycol, 
polyethylene glycol, vegetable oils such as olive oil, and 
injectable organic esters such as ethyl oleate. Examples of 
aqueous solvents are: water, alcoholic-aqueous solutions, 
emulsions or suspensions, including saline and buffered solu 
tions. Examples of parenteral vehicles are: sodium chloride 
solution, Ringer’s dextrose, dextrose and sodium chloride, 
etc. Preservatives and other additives such as, for example, 
antimicrobial agents, anti-oxidants, chelating agents, inert 
gases, etc may also be present. Formulations for topical 
administration may include creams, lotions, gels, drops, sup 
positories, sprays, liquids and powders. Certain conventional 
pharmaceutical carriers, aqueous, oily or powder bases, 
thickeners, etc. may also be necessary or desirable. Compo 
sitions for oral administration may include powders or gran 
ules, suspensions or solutions in water or non-aqueous 
medium, capsules or tablets. The inclusion of thickeners, 
?avorings, diluents, emulsi?ers, dispersants, etc. may be 
desirable. 
For the purposes of the present invention and its descrip 
tion, the term “derivative” of mithramycin must be inter 
preted as a compound covered by the general formula I. 
Likewise, the term “prodrug” of mithramycin must be inter 
preted, for the purposes of the present invention and of the 
description thereof, as any compound releasing mithramycin 
or a derivative, according to general formula I, thereof when 
it circulates in blood or enters the cell. 
Description of a Preferred Embodiment 
The following examples, described in detail, are set forth in 
order to better understand the present invention, which 
examples must be understood without a limiting character for 
the scope of the invention. 
EXAMPLE 1 
Obtaining the Bacterial Strain Slreplomyces 
argillaceus (pLNBIV) 
The strain Slreplomyces argillaceus (pLNBIV) was gener 
ated by means of introducing plasmid pLNBIV in Streptomy 
ces argillaceus ATCC 12956. The introduction of the plasmid 
was carried out by means of protoplast transformation, fol 
lowing standard procedures (Kieser et al., Practical Strepto 
myces genetics, The John Innes Foundation, Norwich, Great 
Britain, 2000). Plasmid pLNBIV has been previously 
described, and contains a series of genes encoding the bio 
synthesis of nucleosidyl diphosphate (NDP)-L-digitoxose 
(Chem. Biol. 2002, 9, 721-729; J. Nat. Prod. 2002, 65, 1685 
1689). The strain Slreplomyces argillaceus (pLNBIV) was 
deposited on 15 Nov. 2006 in the Coleccion Espanola de 
Cultivos Tipo (CECT) [Spanish Type Culture Collection], 
Universidad de Valencia, Campus de Burjassot, 46100 Bur 
jassot (Valencia, Spain) with accession number CECT 3384. 
EXAMPLE 2 
Production of demycarosyl-3D-[3-D-digitoxosyl 
MTM (formula VIII), deoliosyl-3C-0t-L-digitoxosyl 
MTM (formula IX), deoliosyl-3C-[3-D-mycarosyl 
MTM (formula X), and 3A-deolivosyl-MTM 
(formula XI) 
For the puri?cation of the derivatives of MTM, the strain S. 
argillaceus (pLNBIV) was cultured in R5A medium using a 
two-step culture method, as has been previously described (J. 
Bacteriol. 1998, 180, 4929-4937). In the production step, 
eight 2 L Erlenmeyer ?asks were used, each of them contain 
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ing 400 ml of medium, which were incubated for 5 days. The 
cultures were centrifuged and ?ltered, and the broth was 
extracted in solid phase as has been described (Chem. Biol. 
2002, 9, 519-531). The obtained fractions were analyzed by 
HPLC-MS using chromatographic equipment coupled to a 
ZQ4000 mass spectrometer (WatersiMicromass), using as 
solvents acetonitrile and 0.1% tri?uoroacetic acid (TFA) in 
water, and a reversed-phase column (Symmetry C18, 2.1>< 
150 mm, Waters). The samples were eluted with 10% aceto 
nitrile for the ?rst 4 minutes, followed by a 10-88% acetoni 
trile linear gradient for 26 minutes, at a ?ow of 0.25 ml/min. 
Detection and spectral characterization of the peaks was car 
ried out with a photodiode detector and Empower software 
(Waters). The MS analyses were carried out by means of 
positive-mode electrospray ionization, with a capillary volt 
age of 3 kV and cone voltages of 20 and 100 V. Those frac 
tions containing derivatives of MTM (which eluted between 
45 and 55 minutes) were pooled and dried under vacuum. 
This extract was redissolved and chromatographed in a 
uBondapak C18 radial compression column (PrepPak Car 
tridge, 25><100 mm, Waters). An isocratic elution with a mix 
ture of acetonitrile and 0.1% TFA in water (42:58) at 10 
ml/min was used. Demycarosyl-3D-[3-D-digitoxosyl-MTM 
and 3A-deolivosyl-MTM were repuri?ed in a semiprepara 
tive column (Symmetry C18, 7.8><300 mm, Waters) with iso 
cratic elution with acetonitrile and 0.1% TFA in water (37: 
63), at 3 ml/min. Deoliosyl-3C-(x-L-digitoxosyl-MTM and 
deoliosyl-3C-[3-D-mycarosyl-MTM were also repuri?ed 
using the same column and the same solvents, but changing 
the mixture to 45:55. In all cases, after each puri?cation step, 
the collected compounds were diluted 4 times with water and 
desalted and concentrated by means of solid-phase extrac 
tion, in order to be ?nally lyophilized. Thus, 14.3 mg of 
demycarosyl-3D-[3-D-digitoxosyl-MTM (formula VIII), 5.8 
mg of deoliosyl-3C-(x-L-digitoxosyl-MTM (formula IX), 3.3 
mg of deoliosyl-3C-[3-D-mycarosyl-MTM (formula X), and 
10.9 mg of 3A-deolivosyl-MTM (formula XI) were obtained. 
The products were characterized by means of NMR spec 
troscopy and mass spectrometry. The electrospray ionization 
mass spectra (ESI-MS) were acquired using a Thermo Finni 
gan LCQ mass spectrometer, with sample introduction by 
direct diffusion. The high-resolution positive-mode fast atom 
bombardment (FAB) mass spectrometry was acquired using a 
VG70SQ model mass spectrometer (with double-focusing 
magnetic sector). The pseudomolecular ion MS-MS spec 
trometry was performed in both +ve and —ve modes to study 
the fragmentation pattern of the molecule. The UV spectra 
were obtained with a Varian CARY 50 spectrometer, and the 
IR spectra were obtained from KBr discs in a Nicolet Magna 
IR-560 spectrometer. All the NMR data were obtained in 
pyridine d5, using a 400 MHz Varian Inova instrument, 
except the 13C broadband spectra, which were obtained at 
50.3 and 75.4 MHz in 200 and 300 MHz Varian Inova spec 
trometers, respectively. The 6 values were adjusted with ref 
erence to the solvent peaks (6 8.74 ppm and 6 150.35 ppm for 
1H and 13C NMR, respectively). All the NMR assignments 
are based on 1H and 13C spectra using 1H, l3C-HSQC and 
CIGAR-HMBC spectra, 1H, lH-DQ-COSY and NOESY 
spectra, which allowed the unambiguous assignment of all 
NMR signals. Demycarosyl-3D-[3-D-digitoxosyl-MTM (for 
mula VIII) was furthermore studied by means of 1D-TOCSY 
spectra to separately identify the spin patterns of the sugars. 
The chemical structure of the compounds is shown in FIG. 4. 
NMR and MS analysis of demycarosyl-3D-[3-D-digitoxo 
syl-MTM (formula VIII), C51H74OZ4. Negative ESI-MS m/z 
(relative intensity): 1069 (100) [M—H], 1105/1107 (22) 
[M+Cl'], 939 (7) [M—H-Sugar 1A]. Positive ESI-MS m/z 
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(relative intensity): 1093 (100) [M+Na], 1109 (11) [M+K], 
833 (7) [M+H-{Sugar 1A and 1B}+Na], 811 (16) [M+H 
Sugar 1A and 1B], 681 (14) [M+H-Trisaccharide], 421 (18) 
[M+H-Tri- and disaccharide]. HR-FAB m/z [M+Na+]: calcu 
lated, 1093.4467; obtained, 1093.4447. UV/Vis (Methanol) 
kmax (e): 412 (1532), 317 (1663), 279 (5112), 229 (5042) 
nm. IR (KBr) v: 3420 (OH), 2920 (CH), 2848 (CH), 1716 
(C:O), 1631 (C:O), 1514(C:C),1382, 1130,1064 cm“. 
Table 1 shows the 1H-NMR and 13 C-NMR data. 
NMR and MS analysis of deoliosyl-3C-0t-L-digitoxosyl 
MTM (formula IX), C52H76Oz4. Negative ESI-MS m/z (rela 
tive intensity): 1083 (100) [M—H], 1119/1121 (26) [M+Cl‘]. 
Positive ESI-MS m/z (relative intensity): 1107 (100) 
[M+Na+], 1123 (13) [M+K+], 847 (5) [M+H-{Disaccha 
ride}+Na], 825 (27) [M+H-Disaccharide], 681 (11) [M+H 
Trisaccharide], 551 (34) [M+H-Sugars 1A, 1B, 1D and 1E] 
and 421 (22) [M+H-Tri- and disaccharide]. HR-FAB m/z 
[M+Na+]: calculated, 1107.4603; obtained, 1107.4624. 
UV/Vis (Methanol) kmax (e): 412 (2148), 317 (2491), 278 
(6851), 230 (6420) nm. IR (KBr) v: 3409 (OH), 2924 (CH), 
2850 (CH), 1716 (C:O), 1634 (C:O), 1514 (C:C), 1374, 
1126, 1064 cm_l. Table 2 shows the 1H-NMR and l3C-NMR 
data. 
NMR and MS analysis of deoliosyl-3C-[3-D-mycarosyl 
MTM (formula X), C46H66OZI. Negative ESI-MS m/z (rela 
tive intensity): 953 (100) [M—H]. Positive ESI-MS m/z (rela 
tive intensity): 977 (100) [M+Na+], 993 (5) [M+K+], 695 (8) 
[M-Sugar 1A and 1B], 681 (10) [M-Sugar 1C and 1D] and 
421 (20) [M+H-bis-disaccharide]. HR-FAB m/z [M+Na+]: 
calculated, 977.3745; obtained, 977.3948. UV/Vis (Metha 
nol) kmax (e): 412 (1357), 316 (1629), 278 (3274), 230 
(2982) nm. IR (KBr) v: 3425 (OH), 2924 (CH), 2850 (CH), 
1716 (C:O), 1631 (C:O), 1514 (C:C), 1374, 1122, 1064 
cm_l. Table 3 shows the 1H-NMR and 13 C-NMR data. 
NMR and MS analysis of 3A-deolivosyl-MTM (formula 
XI), C46H66OZI. Negative ESI-MS m/z (relative intensity): 
953 (100) [M—H], 989/991 (9) [M+Cl‘], 823 (5) [M-Sugar 
1B], 809 (8) [M+H-Sugar 1D]. Positive ESI-MS m/z (relative 
intensity): 955 (100) [M+Na+], 993 (10) [M+K+], 833 (13) 
[M+H-{Sugar1D}+Na+],825 (11) [M+H-Sugar1B], 695 (5) 
[M+H-Sugar 1A and 1B], 681 (25) [M+H-Sugar 1C and 1D], 
551 (50) [M+H-Sugars 1A, 1B and 1D] and 421 (33) [M+H 
Tri- and monosaccharide]. HR-FAB m/z [M+Na+]: calcu 
lated, 977.3735; obtained, 977.3950. UV/Vis (Methanol) 
kmax (e):412 (2178), 316 (2310), 278 (8099), 231 (7363)nm. 
IR (KBr) v: 3421 (OH), 2924 (CH), 2850 (CH), 1716 (C:O), 
1634 (C:O), 1514 (C:C), 1374, 1122, 1060 cm_l. Table 4 
shows the 1H-NMR and l3C-NMR data. 
EXAMPLE 3 
Obtaining the Slreplomyces argillaceus (pFL845) 
Bacterial Strain 
The strain Slreplomyces argillaceus (pFL845) was gener 
ated by means of introducing plasmid pFL845 in Streptomy 
ces argillaceus. The introduction of the plasmid was carried 
out by means of protoplast transformation, following stan 
dard procedures (Kieser et al., Practical Slreplomyces genet 
ics, The John Innes Foundation, Norwich, Great Britain, 
2000). Plasmid pFL845 has been previously described, and 
contains a series of genes encoding the biosynthesis of nucle 
osidyl diphosphate (NDP)-D-amicetose (Chem. Commun. 
(Camb). 2005 Mar. 28; (12): 1 604-6). The strain Slreplomyces 
argillaceus (pFL845) was deposited on 15 Nov. 2006 in the 
Coleccion Espanola de Cultivos Tipo (CECT) [Spanish Type 
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Culture Collection], Universidad de Valencia, Campus de 
Burj assot, 46100 Burjassot (Valencia, Spain) with accession 
number CECT 3383. 
EXAMPLE 4 
Production of demycarosyl-MTM (formula XII) and 
6-dediolivosyl-6-[3-D-amicetosyl-MTM (formula 
XIII) 
To purify the novel derivatives of mithramycin produced 
by S. argillaceus (pFL845), this strain was cultured in eight 2 
L ?asks containing 400 ml of R5A medium supplemented 
with thiostrepton (5 p1ng f.c.). After 6 days of incubation at 
30° C., the cultures were centrifuged, ?ltered and a solid 
phase extraction was carried out. The extract was then sub 
jected to a ?rst chromatography using a uBondapak C18 
cartridge. The elution was carried out at 10 ml/min using a 
mixture of acetonitrile and TFA in water (42:58) as a mobile 
phase. A second chromatography was then carried out in 
Symmetry C18 (7.8><300), at 3 ml/min using a mixture of 
acetonitrile and TFA in water (37:63, for 845-1 P1; 42:58, for 
845-1 P3) as a mobile phase. The following yield was 
obtained: 16.1 mg of demycarosyl-MTM (formula XII) and 
4.3 mg of 6-dediolivosyl-6-[3-D-amicetosyl-MTM (formula 
XIII). The products were characterized by HPLC-MS, as 
described in Example 2. 
NMR and MS analysis of demycarosyl-MTM (formula 
XII), C45H64OZI. Amorphous yellow solid. [0t]st —25 (c 
0.032, MeOH); Negative ESI-MS m/z (relative intensity): 
939 (100) [M—H], 975/977 (28) [M+Cl‘], 809 (10) [M—H 
{sugarA}], 679(5) [M—H-{Disaccharide}]. Positive ESI-MS 
m/z (relative intensity): 963 (100) [M+Na+], 979 (10) 
[M+K+], 833 (9) [M+H-{Sugar A}+Na+], 811 (5) [M+H 
sugar A], 681 (20) [M+H-{disaccharide}], 703 (8) [M+H 
{Disaccharide}+Na], 421 (15) [M+H-{bis-disaccharide}]. 
HR-FAB m/z [M+Na+]: calculated, 963.3804; obtained, 
963.3793. UV/Vis (Methanol) kmax (e): 430 (10,200), 316 
(6400), 281 (50,400), 231 (11,000) nm. IR (KBr) v: 3421 
(OH), 2924 (CH), 2850 (CH), 1716 (C:O), 1631 (C:O), 
1514 (C:C), 1374, 1122, 1064 cm_l. Table 5 shows the 
1H-NMR and 13C-NMR data. 
NMR and MS analysis of 6-dediolivosyl-6-[3-D-amiceto 
syl-MTM (formula XIII), C46H66OZO. Amorphous yellow 
solid. [0t]25D —22 (c 0.027, MeOH); Negative ESI-MS m/z 
(relative intensity): 937 (100) [M—H], 973/975 (23) [M+Cl'], 
823 (10) [M—H-{sugar A}]. Positive ESI-MS m/z (relative 
intensity): 961 (100) [M+Na+], 977 (15) [M+K+], 825 (10) 
[M+H-{sugarA}], 535 (9) [M+H-{Trisaccharide}], 421 (12) 
[M+H-{Tri- and monosaccharide}]. HR-FAB m/z [M+Na+]: 
calculated, 961.4053; obtained, 961.4045. UV/Vis (Metha 
nol) kmax (e):430 (10,500), 316 (6,500), 281 (48,400), 230 
(12,600). IR (KBr) v: 3425 (OH), 2928 (CH), 2850 (CH), 
1716 (C:O), 1631 (C:O), 1514 (C:C), 1374, 1122, 1064 
cm_l. Table 6 shows the 1H-NMR and l3C-NMR data. 
EXAMPLE 5 
Obtaining the Slreplomyces argillaceus (pFL942) 
Bacterial Strain 
The strain Slreplomyces argillaceus (pFL942) was gener 
ated by means of introducing plasmid pFL942 in Streptomy 
ces argillaceus. The introduction of the plasmid was carried 
out by means of protoplast transformation, following stan 
dard procedures (Kieser et al., Practical Slreplomyces genet 
ics, The John Innes Foundation, Norwich, Great Britain, 
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2000). Plasmid pFL942 has been previously described, and 
contains a series of genes encoding the biosynthesis of nucle 
osidyl diphosphate (NDP)-L-mycarose (Chemistry & Biol 
ogy. 2004, (11):1709-18). The strain Slreplomyces argilla 
ceus (pFL942) was deposited on May 2, 2008 in the 
Coleccion Espa?ola de Cultivos Tipo (CECT) [Spanish Type 
Culture Collection], Universidad de Valencia, Campus de 
Burjassot, 46100 Burj assot (Valencia, Spain) with accession 
number CECT 7368. 
EXAMPLE 6 
Production of deoliosyl-demycarosyl-3C-[3-D-boivi 
nosyl-MTM (formula XVII) and demycarosyl-3D-[3 
D-digitoxosyl-MTM (formula VIII) 
To purify the novel derivatives of mithramycin produced 
by S. argillaceus (pFL942), this strain was cultured in R5A 
solid medium. 100 Agar plates were uniformly inoculated 
with spores and after 6 days of incubation at 28° C., the 
cultures were extracted 3 times with ethyl acetate. The extract 
was then subjected to a ?rst chromatography using a uBonda 
pak C18 radial compression cartridge. The elution was car 
ried out at 10 ml/min using a mixture of acetonitrile and TFA 
in water (50: 50) as a mobile phase. A second chromatography 
was then carried out in a Sun?re PrepC18 column (10x250 
mm, Waters), at 7 ml/min using a mixture of acetonitrile and 
0.1% TFA in water (37:63) as a mobile phase. The HPLC 
fractions were collected on 0.1M potassium phosphate buffer 
(pH:7) and after each puri?cation, the samples were diluted 
4 times with water, desalted, concentrated and lyophilized. 
The following yield was obtained: 3 mg of deoliosyl-demy 
carosyl-3C-[3-D-boivinosyl-MTM (formula XVII) and 6.9 
mg of demycarosyl-3D-[3-D-digitoxosyl-MTM (formula 
VIII). The products were characterized by HPLC-MS, as 
described in Example 2. The compound demycarosyl-3D-[3 
D-digitoxosyl-MTM (formula VIII) is characterized in 
Example 2. 
NMR and MS analysis of deoliosyl-demycarosyl-3C-[3-D 
boivinosyl-MTM (formula XVII), C45H64OZI. Amorphous 
yellow solid. [0t]st —22 (c 0.029, MeOH); Negative ESI-MS 
m/z (relative intensity): 939 (100) [M—H]. Positive ESI-MS 
m/z (relative intensity): 963 (100) [M+Na+], 979 (10) 
[M+K+], 833 (10) [M+Na+-{Sugar A}], 703 (50) [M+H 
{disaccharide}], 443 (12) [aglycon+Na+]. HR-FAB m/z 
[M+Na+]: calculated, 939.3849; obtained, 939.3867. UV/Vis 
(Methanol) kmax (e):430 (10,600), 3 17 (6800), 281 (49,500), 
230 (10,000) nm. IR (KBr) v: 3431 (OH), 2926 (CH), 2851 
(CH), 1716 (C:O), 1631 (C:O), 1514 (C:C), 1374, 1121, 
1064 cm“. Table 7 shows the 1H-NMR and l3C-NMR data. 
EXAMPLE 7 
Obtaining the Bacterial Strain Slreplomyces 
argillaceus M7U1 (pFL845) 
The strain Slreplomyces argillaceus M7U1 (pFL845) was 
generated by means of introducing plasmid pFL845 in Strep 
Zomyces argillaceus M7U1. The introduction of the plasmid 
was carried out by means of protoplast transformation, fol 
lowing standard procedures (Kieser et al., Practical Strepto 
myces genetics, The John Innes Foundation, Norwich, Great 
Britain, 2000). The strain Slreplomyces argillaceus M7U1 
has been previously described (Mol. Gene. Genet. 2001, 264, 
827-835). Plasmid pFL845 has been previously described, 
and contains a series of genes encoding the biosynthesis of 
nucleosidyl diphosphate (NDP)-D-D-amicetose (Chem. 
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Commun. (Camb). 2005 Mar. 28; (12):1604-6). The strain 
Slreplomyces argillaceus M7U1 (pFL845) was deposited on 
May 2, 2008 in the Coleccion Espanola de Cultivos Tipo 
(CECT) [Spanish Type Culture Collection], Universidad de 
Valencia, Campus de Burjassot, 46100 Burjassot (Valencia, 
Spain) with accession number CECT 7369. 
EXAMPLE 8 
Production of 6-dediolivosyl-6-[3-D-amicetosyl-deo 
liosyl-demycarosyl-3C-[3-D-boivinosyl-MTM (for 
mula XVIII); deoliosyl-demycarosyl-3C-[3-D-olivo 
syl-3D-[3-D-digitoxosyl-MTM (formula XIX); 
6-dediolivosyl-6-[3-D-amicetosyl-deoliosyl-demy 
carosyl-3C-[3-D-olivosyl-3D-[3-D-digitoxosyl-MTM 
(formula XX) and 6-dediolivosyl-6-[3-D-amicetosyl 
deoliosyl-3C-[3-D-olivosyl-MTM (formula XXI) 
To purify the novel derivatives of mithramycin produced 
by S. argillaceus M7U1 (pFL845), this strain was cultured in 
R5A solid medium. 100 Agar plates were uniformly inocu 
lated with spores and after 6 days of incubation at 28° C., the 
cultures were extracted 3 times with ethyl acetate. The extract 
was then subj ected to a ?rst chromatography using a uBonda 
pak C18 radial compression cartridge. The elution was car 
ried out at 10 ml/min using a mixture of acetonitrile and TFA 
in water (50: 50) as a mobile phase. A second chromatography 
was then carried out in a Sun?re PrepC18 column (10x250 
mm, Waters), at 7 ml/min using a mixture of acetonitrile and 
0.1% TFA in water (40:60) as a mobile phase. The HPLC 
fractions were collected on 0.1M potassium phosphate buffer 
(pH:7) and after each puri?cation, the samples were diluted 
4 times with water, desalted, concentrated and lyophilized. 
The following yield was obtained: 1.7 mg of 6-dediolivosyl 
6-[3-D-amicetosyl-deoliosyl-demycarosyl-3C-[3-D-boivino 
syl-MTM (formula XVIII), 6.7 mg of deoliosyl-demy 
carosyl-3C-[3-D-olivosyl-3D-[3-D-digitoxosyl-MTM 
(formula XIX), 12.2 mg of 6-dediolivosyl-6-[3-D-amicetosyl 
deoliosyl-demycarosyl-3C-[3-D-olivosyl-3D-[3-D-digitoxo 
syl-MTM (formula XX) and 17 mg of 6-dediolivosyl-6-[3-D 
amicetosyl-deoliosyl-3C-8-D-olivosyl-MTM (formula 
XXI). The products were characterized by HPLC-MS, as 
described in Example 2. 
NMR and MS analysis of 6-dediolivosyl-6-[3-D-amiceto 
syl-deoliosyl-demycarosyl-3C-[3-D-boivinosyl-MTM (for 
mula XVIII): C39H54Ol7. Amorphous yellow solid. [0t]st 
—23 (c 0.026, MeOH); Negative ESI-MS m/Z (relative inten 
sity): 793 (10%) [M—H], 777 (100%) (M—H20). Positive 
ESI-MS m/Z (relative intensity): 795 (25) [M+H], 817 (20) 
[M+Na+], 687 (100), [M+H-{sugar A}], 673 (11) 
[M+H{sugarA and 1C}], 443 (12) [aglycon+Na]. HR-FAB 
m/Z [M+Na+]: calculated, 817.3253; obtained, 817.3238. 
UV/Vis (Methanol) kmax (e): 430 (10,800), 316 (6700), 280 
(50,700), 231 (13,000) nm. IR (KBr) v: 3428 (OH), 2925 
(CH), 2850 (CH), 1716 (C:O), 1632 (C:O), 1514 (C:C), 
1374, 1121, 1063 cm“. Table 8 shows the 1H-NMR and 
13 C-NMR data. 
NMR and MS analysis of deoliosyl-demycarosyl-3C-[3-D 
olivosyl-3D-[3-D-digitoxosyl-MTM (formula XIX), 
C51H74OZ4. Amorphous yellow solid. [0t]st —21 (c 0.020, 
MeOH); Negative ESI-MS m/Z (relative intensity): 1069 (20) 
[M—H]. Positive ESI-MS m/Z (relative intensity): 1071 (48) 
[M+H], 1093 (26) [M+Na+], 963 (28) [M+Na+-{monosac 
charide}], 833 (16)) [M+Na+-{disaccharide}], 703 (12) 
[M+Na+-{Trisaccharide}], 550 (14) [M+Na+-{tetrasaccha 
ride], 443 (26) [M+H-{Tri- and disaccharide}]. HR-FAB m/ Z 
[M+Na+]: calculated, 1093.4462; obtained, 1093.4447. 
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UV/Vis (Methanol) kmax (e): 430 (10,600), 316 (6500), 280 
(49,500), 231 (12,800) nm. IR (KBr) v: 3423 (OH), 2921 
(CH), 2850 (CH), 1716 (C:O), 1631 (C:O), 1514 (C:C), 
1382, 1131, 1064 cm'. Table 9 shows the 1H-NMR and 13C 
NMR data. 
NMR and MS analysis of 6-dediolivosyl-6-[3-D-amiceto 
syl-deoliosyl-demycarosyl-3C-[3-D-olivosyl-3D-[3-D-digi 
toxosyl-MTM (formula XX), C45H6ZOZO.Amorphous yellow 
solid. [0t]st —15 (c 0.024, MeOH); Positive ESI-MS m/Z 
(relative intensity): 947 (25) [M+Na+], 817 (100) [M+Na+ 
{sugar C}], 795 (12) [M+H-sugar C]. HR-FAB m/Z 
[M+Na+]: calculated, 947.3883; obtained, 947.3867. UV/Vis 
(Methanol) kmax (e): 430 (10,400), 316 (6500), 281 (48, 
000), 232 (11,900) nm. IR (KBr) v: 3426 (OH), 2928 (CH), 
2843 (CH), 1716 (C:O), 1632 (C:O), 1514 (C:C), 1374, 
1121, 1063 cm'. Table 10 shows the 1H-NMR and l3C-NMR 
data. 
NMR and MS analysis of 6-dediolivosyl-6-[3-D-amiceto 
syl-deoliosyl-3C-[3-D-olivosyl-MTM (formula XXI), 
C45H64OZI. Negative ESI-MS m/Z (relative intensity): XXX. 
Positive ESI-MS m/Z (relative intensity): XXX. HR-FAB m/ Z 
[M+Na+]: calculated, 940.39; obtained, XXX. UV/Vis 
(Methanol) kmax (6): XXX. IR (KBr) v: XXX. Table 11 
shows the 1H-NMR and l3C-NMR data. 
EXAMPLE 9 
Antitumor activity of demycarosyl-3D-[3-D-digitoxo 
syl-MTM (formula VIII), deoliosyl-3C-(x-L-digi 
toxosyl-MTM (formula IX), deoliosyl-3C-[3-D-my 
carosyl-MTM (formula X), 3A-deolivosyl-MTM 
(formula XI), demycarosyl-MTM (formula XII), 
6-dediolivosyl-6-[3-D-amicetosyl-MTM (formula 
XIII) 
deoliosyl-demycarosyl-3C-[3-D-boivinosyl-MTM [for 
mula QiVII)]; 6-dediolivosyl-6-[3-D-amicetosyl-deoliosyl 
demycarosyl-3C-[3-D-boivinosyl-MTM [formula (XVIII)]; 
deoliosyl-demycarosyl-3C-[3-D-olivosyl-3D-[3-D-digitoxo 
syl-MTM [formula (XIX)]; 6-dediolivosyl-6-[3-D-amiceto 
syl-deoliosyl-demycarosyl-3C-[3-D-olivosyl-3D-[3-D-digi 
toxosyl-MTM [formula QiX)], and 6-dediolivosyl-6-[3-D 
amicetosyl-deoliosyl-3C-[3-D-olivosyl-MTM [formula 
09(1)] 
The derivatives of MTM were assayed against a series of 
cell lines from tumors. Cell growth and viability were quan 
titatively determined, using a colorimetric type assay, using 
the reaction with sulforhodamine B (SRB) according to the 
technique described by Faircloth et al. (Journal of?ssue and 
Culture Methods 1988, 11, 201 -205). The results are shown in 
Table 5. 
96-well microtiter plates were inoculated with cells (5 ><103 
cells per well) in aliquots of 195 pl of medium, incubating 
them for 18 hours in medium without added compound, to 
allow the cells to adhere to the surface. The compounds to be 
assayed were then added, in 5 [11 samples, in a concentration 
range from 10 to 10'8 ug/ml, dissolved in DMSO/EtOH 
(0.2% in PS buffer).After 48 hours of exposure, the antitumor 
effect was measured using the SRB technique: the cells were 
?xed adding 50 pl of 50% (w/v) cold trichloroacetic acid and 
incubated for 60 minutes at 4° C. The plates were washed with 
deionized water and dried. 100 pl of SRB solution (0.4% w/v 
in 1% acetic acid) were added to each well, and incubated for 
10 minutes at room temperature. The non-bound SRB was 
eliminated, washing with 1% acetic acid. The plates were air 
dried and the bound dye was dissolved with Tris buffer. Opti 
cal densities were read in an automatic plate spectrophotom 














